TrialPharmacology research & perspectives2018

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

Jan Hillson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.